Type 2 Diabetes and Simvastatin

4001

A South Carolina study indicates that simvastatin (Zocor), an oral “statin” lipid-lowering drug is a potentially beneficial treatment for the inflammatory reaction associated with atherosclerosis.

Twenty-six patients with type 2 diabetes participated in the study. They were started on a lipid-lowering diet and encouraged to exercise in addition to receiving Zocor treatment that was adjusted until LDL cholesterol levels reached 100 mg/dl or lower.

A1C levels remained constant throughout the study. There was a highly significant reduction in blood levels of immune complexes containing modified lipoproteins after three to six months of treatment with Zocor.

Levels returned to baseline after Zocor use was discontinued.

Researchers note this may represent an additional mechanism for the reduced incidence of cardiovascular events in patients treated with Zocor.

—Diabetes Care, April 2004

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.